Modulation of Striatal Dopamine and Acetylcholine Release by Different Glutamate Receptors: Studies with in Vivo Microdialysis

  • Mario Herrera-Marschitz
Part of the Advances in Behavioral Biology book series (ABBI, volume 39)


There is evidence that striatal dopamine (DA) release is presynaptically modulated by a glutamatergic cortical input (see1,2,3) In the caudate of the push-pull cannulated cats4, as well as in striatal slice preparations in rats5, glutamate stimulates DA release. It was proposed4, that the DA stimulation produced by glutamate reflected direct axonal interactions between cortical glutamatergic and mesencephalic dopaminergic afferents, since the stimulating effect of L-glutamate was still observed in the presence of tetrodotoxin. This hypothesis has received some support from biochemical and histochemical studies showing direct intrastriatal axonal interactions between cortico-striatal projections and nigro-striatal DA terminals labeled with antibodies against the enzyme tyrosine hydroxylase5,6. However, the majority of the striatal afferents from the cortex and the substantia nigra make axodendritic synaptic contacts with striatal neurons7, giving a basis for polysynaptic loops including gamma-aminobutyric acid (GABA) and/or acetylcholine (ACh) neurons, by which cortical glutamate neurons could also modulate striatal dopamine release. There is now evidence that the excitatory action of glutamate is conveyed by multiple receptors, which have been pharmacologically differentiated and characterized, i.e. N-methyl-D-aspartate (NMDA)-, quisqualate- and kainate-receptors. All these receptors are found in the striatum (see8), but they appear located on different cells or associated with different synapses, thereby related to different functions. Indeed, it has been shown, that, in the cat caudate, cortically evoked monosynaptic excitatory postsynaptic potentials (EPSPs) are mediated by kainate or quisqualate, but not by NMDA receptors9. The present studies with in vivo microdialysis10 show that, in the striatum, in situ kainic acid (KA) stimulation increases DA, but decreases ACh. However, while NMDA is less potent that KA on DA release, it induces a dose-dependent increase in striatal AC release. Furthermore, it was found that cortical stimulation with either KA or NMDA produced a dose-dependent increase in striatal ACh release, but only a minor increase in striatal DA release.


High Performance Liquid Chromatography Kainic Acid Striatal Dopamine Microdialysis Probe Perfusion Medium 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    A. Cheramy, R Romo, G. Godeheu, P. Baruch and J. Glowinski, In vivo presynaptic control of dopamine release in the cat caudate nucleus - II. Facilitatory or inhibitory influence of 1-glutamate, Neuroscience 19: 1081 (1986).PubMedCrossRefGoogle Scholar
  2. 2.
    R. Romo, A. Cheramy, G. Godeheu, and J. Glowinski, In vivo presynaptic control of dopamine release in the cat caudate nucleus -I. Opposite changes in neuronal activity and release evoked from thalamic motor nuclei, Neuroscience 19: 1079 (1986).Google Scholar
  3. 3.
    R. Romo, A. Cheramy, G. Godeheu and J. Glowinski, In vivo presynaptic control of dopamine release in the cat caudate nucleus -III. Further evidence for the implication of corticostriatal glutamatergic neurons, Neuroscience 19: 1091 (1986).PubMedCrossRefGoogle Scholar
  4. 4.
    M.F. Giorguieff, M.L. Kemel and J. Glowinski, Presynaptic effect of Lglutamic acid on the release of dopamine in rat striatal slices, Neuroscience Lett. 6: 73 (1977).CrossRefGoogle Scholar
  5. 5.
    P.J. Roberts and N.A. Sharif, Striatal glutamatergic function: modifications following specific lesions, Brain Res. 235: 83 (1982).PubMedCrossRefGoogle Scholar
  6. structural analysis of the relation between cortico inputs and tyrosine hydroxylase-containing terminals in rat neostriatum, Brain Res. 302: 267 (1984).CrossRefGoogle Scholar
  7. 7.
    P. Somogyi, J.P. Bolam and A.D. Smith, Monosynaptic cortical input and local axon collaterals of identified striatonigral neurons. A light and electron microscopy study using the Golgi-peroxidase transport-degeneration procedure, J. Comp. Neurol. 195: 567 (1981).PubMedCrossRefGoogle Scholar
  8. 8.
    C.W. Cotman, D.T. Monaghan, O.P. Ottersen and J. Storm-Mathisen, Anatomical organization of excitatory amino acid receptors and their pathways, TINS 10: 273 (1987).Google Scholar
  9. 9.
    P.L. Herrling, Pharmacology of the corticocaudate excitatory postsynaptic potential in the cat: evidence for its mediation by quisqualate-or kainate-receptors, Neuroscience 14: 417 (1985).PubMedCrossRefGoogle Scholar
  10. 10.
    U. Ungerstedt, M. Herrera-Marschitz, U. Jungnelius, L. Stâhle, L. Tossman and T. Zetterström, Dopamine synaptic mechanisms reflected in studies combining behavioural recordings and brain dialysis, in: “Advances in dopamine research, Advances in the Biosciences 37”, M. Kohsaka, T. Shomori, Y. Tsukada and G.N. Woodruff, eds, Pergamon Press, Oxford (1982).Google Scholar
  11. 11.
    K. Zilles, The cortex of the rat. A stereotaxic atlas, Springer, Berlin (1985).Google Scholar
  12. 12.
    M. Reid, M. Herrera-Marschitz, T. Hökfelt, L. Terenius and U. Ungerstedt, Differential modulation of striatal dopamine release by intranigral injection of gamma-aminobutyric acid (GABA), dynorphin A and substance P, Eur. J. Pharmacology 147: 411 (1988)CrossRefGoogle Scholar
  13. 13.
    D. Maysinger, M. Herrera-Marschitz, A. Carlsson, L. Garofalo, A.C. Cuello and U. Ungerstedt, Striatal and cortical acetylcholine release in vivo in rats with unilateral decortication: effects of treatments with monoganglioside GM1, Brain Res. 461: 355 (1988).PubMedCrossRefGoogle Scholar
  14. 14.
    C.J. Carter, R. L’Heureux and B. Scatton, Differential control of Nmethyl-D-aspartate and kainate of striatal dopamine release in vivo: a trans-striatal dialysis study, J. Neurochemistry 51: 462 (1988).CrossRefGoogle Scholar

Copyright information

© Plenum Press, New York 1991

Authors and Affiliations

  • Mario Herrera-Marschitz
    • 1
  1. 1.Department of PharmacologyKarolinska institutetStockholmSweden

Personalised recommendations